GTC
RAPT

Ghost Tree Capital’s RAPT Therapeutics RAPT Stock Holding History

Ghost Tree Capital’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,625
Closed -$2.48M – 62
2022
Q4 		$2.48M Buy
15,625
+4,375
+39% +$700K 1.06% 26
2022
Q3 		$2.17M Sell
11,250
-9,375
-45% -$1.77M 0.61% 36
2022
Q2 		$3.01M Sell
20,625
-10,625
-34% -$1.42M 1.57% 25
2022
Q1 		$5.5M Sell
31,250
-12,500
-29% -$2.36M 1.19% 19
2021
Q4 		$12.9M Buy
43,750
+12,500
+40% +$3.34M 4.61% 5
2021
Q3 		$7.76M Sell
31,250
-40,000
-56% -$10.6M 2.27% 15
2021
Q2 		$18.1M Buy
+71,250
New +$13.3M 4.98% 2
2020
Q4 		– Sell
-14,375
Closed -$3.7M – 53
2020
Q3 		$3.7M Buy
+14,375
New +$3.19M 1.07% 28

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ghost Tree Capital's RAPT Position: Q1 2023 in Review

Ghost Tree Capital sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 15,625 shares — an estimated $2.48M sold.

Ghost Tree Capital first reported a position in RAPT in Q3 2020 and held it in 8 quarters. The position peaked at $18.1M in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

  • Ghost Tree Capital reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 15,625 RAPT Therapeutics shares in Q1 2023, an estimated $2.48M.
  • Ghost Tree Capital first reported a position in RAPT Therapeutics in Q3 2020 and held it in 8 quarters.
  • Ghost Tree Capital's RAPT Therapeutics position peaked at $18.1M in Q2 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Ghost Tree Capital's 13F filing for Q1 2023, filed 15 May 2023.